| 1Brackstone M,Townson JL,Chambers AF,et al.Tumour dormancy in breast canc-er:An update[J].Breast Cancer Res,2007,9(3):208-208.
2Vito Lorusso.Target-based therapies in breast cancer:current status and future per-spectives[J].Biologics,2008,2(4):813-821.
3Aesoy R,Sanchez BC,Norum JH,et al.An autocrine VEGF/VEGFR2and p38signaling loop confers resistance to4-hydroxytamoxifen in MCF-7breast cancer cells[J].Mol Cancer Res,2008,6(10):1630-1638.
4Maura N,Dickler1,Hope S,et al.A Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer[J].Clin Cancer Res,2008,14(23):7878-7883.
5Ferraar N.Vascular endothelial growth factor:basic science and clinical progress[J].Endocr Rev,2004,25(4):581-611.
6Le XF,Mao W,Lu C,et al.Specific blockade of VEGF and Her2pathways results in greater growth inhibition of breast cancer xenografts that overexpress Her2[J].Cell Cycle,2008,7(23):3747-3758.
7Nathanson SD.Insights into the mechanisms of lymph node metastasis[J].Canc-er,2003,98(2):413-423.
8Vincenti V,Cassano C,Rocchi M,et al.Assingnment of the vascular endothelial growth-factor gene to the human chromosome6p21.3[J].Circulation,1996,93(8):1493-1495.
9Wang R,Crystal RG,Hackett NR.Identification of an exonic splicing silencer in exon6A of the human VEGF gene[J].BMC Mol Biol,2009,10:103.
10Konecny GE,Meng YG,Untch M,et al.Association between Her-2/neu and vas-cular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients[J].Clin Cancer Res,2004,10(5):1706-1716.
11Sledge GW Jr.Vascular endothelial growth factor in breast cancer:biologic and therapeutic aspects[J].Semin Oncol,2002,29(3):104-110.
12Dot C,Parier V,Behar-Cohen F,et al.Influence of age on retinochoroidal healing processes after argon photocoagulation in C57bl/6j mice[J].Mol Vis,2009,15:670-684.
13Vumbaca F,Phoenix KN,Rodriguez-Pinto D,et al.Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability,translation,and breast cancer angiogenesis[J].Mol Cell Biol,2008,28(2):772-783.
14Jakovljevic G,Culic S,Stepan J,et al.Vascular endothelial growth factor in chil-dren with neuroblastoma:a retrospective analysis[J].Exp Clin Cancer Res,2009,28:143.
15Yoshimura T,Sonoda KH,Sugahara M,etal.Comprehensive analysis of inflamma-tory immune mediators in vitreoretinal diseases[J].Plos One,2009,4(12):e8158:1-9.
16Cao D,Hou M,Guan YS,et al.Expression of HIF-1alpha and VEGF in colorectal cancer:association with clinical outcomes and prognostic implications[J].BMC Cancer,2009,9:432.
17Cao Y,Linden P,Shima D,et al.In vivo angiogenic activity and hypoxia inductio of geterodimers of placenta growth factor/vascular endothelial growth factor[J].Clin Invest,1996,98:2507-2511.
18Bando H.Vascular endothelial growth factor and bevacitumab in breast cancer[J].Breast Cancer,2007,14(2):163-173.
19Gordon MS,Margolin K,Talpaz M,etal.Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with ad-vanced cancer[J].Clin Oncol,2001,19:843-850.
20Zhang L,Hannay JA,Liu J,et al.Vascular endothelial growth factor overexpres-sion by soft tissue sarcom a cells:implications for tumor growth,metastasis and chemoresistance[J].Cancer Res,2006,66(17):8770-8778.
21Heer K,Kumar H,Read J,et al.Serum vascular endothelial growth factor in breast cancer.its relation with cancer type and estrogen receptor status[J].Clin Cancer Res,2001,7(11):3491-3494.
22Adams J,Carder PJ,Downey S,et al.Vascular endothelial growth factor in breast cancer.comparison of plasma,serum,and tissue VEGF and microvessel density and efects of tamoxifen[J].Cancer Res,2000,60(11):2898-2905.
23Vito Lorusso.Bevacizumab in the treatment of Her2-negative breast cancer[J].Biologics,2008,2(4):813-821.
24Rosen LS.VEGF-targeted therapy:therapeutic potential and recent advances[J].Oncologist,2005,10(6):382-391.
25Cesare G,Paolo M,Antonio R,et al.The role of bevacizumab in the treatment of non-small cell lung cancer:current Indications and future developments[J].The Oncologist,2007,12(10):1183-1193.
26Hope S.Rugo,bevacizumab in the treatment of breast cancer:Rationale and cur-rent data[J].The Oncologist,2004,9(1):43-49.
27Sledge GW,Neuberg D,Bernardo P,et al.Phase III trial of doxorubicin,paclitax-el,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial(E1193)[J].Clin Oncol,2003,21:588-592.
28O'Shaughnessy J,Miles D,Vukelja S,et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with ad-vanced breast cancer:phase III trial results[J].Clin Oncol,2002,20:2812-2823.
29Miller KD,Chap LI,Holmes FA,et al.Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer[J].Clin Oncol,2005,23:792-799.
30Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357:2666-2676. |
